RxDoctor Payments Data

Erin Blackstock, MD

Pulmonary Disease · Salt Lake City, UTNPI 1790123339

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,300 of the $6,700 with a category attached, or 64.2%. United Therapeutics Corporation accounts for 92.7% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $6,279, more than ten times the $100 reported in 2019.

$6,700in general payments, 2019–2025

Across 25 payments — averaging $267.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$6K
  • Boehringer Ingelheim$301
  • Genentech USA, Inc.$100
  • Jazz Pharmaceuticals Inc.$59
  • Viatris Specialty LLC$23
  • Inogen, Inc.$8
$242,182in research payments, 2019–2025

Across 86 payments — averaging $2816.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$205K
  • United Therapeutics Corporation$27K
  • Boehringer Ingelheim International GmbH$11K

What the payments were for

  • Consulting fees$4,30064%
  • Travel & lodging$88513%
  • Food & beverage$1,41521%
  • Education$1001%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,700 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Utah.

See all pulmonary disease providers in Utah

Medicare billing

Part B allowed, 2024
$21,975
Medicare patients
151
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$32,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,585
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$6,458
SymbicortBudesonide/Formoterol Fumarate17$4,881
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,896
Albuterol Sulfate HfaAlbuterol Sulfate17$559
Mycophenolate Mofetil11$528
Azithromycin26$408
Omeprazole18$350
Prednisone46$174
Montelukast Sodium11$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimStiolto Respimat$301$6,45815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 pulmonary disease providers in Utah.

Other pulmonary disease in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →